Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) has been assigned an average rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $3.81.
A number of equities research analysts have issued reports on EYPT shares. HC Wainwright reaffirmed a “hold” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, February 4th. ValuEngine raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Laidlaw started coverage on Eyepoint Pharmaceuticals in a research report on Monday, November 4th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Zacks Investment Research raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research report on Thursday, January 30th.
EYPT stock traded down $0.07 during mid-day trading on Friday, reaching $1.78. The company had a trading volume of 308,488 shares, compared to its average volume of 522,527. The company has a debt-to-equity ratio of 3.12, a quick ratio of 4.29 and a current ratio of 4.54. The company has a market capitalization of $200.56 million, a price-to-earnings ratio of -3.07 and a beta of 1.58. The firm has a fifty day simple moving average of $1.71 and a 200 day simple moving average of $1.70. Eyepoint Pharmaceuticals has a fifty-two week low of $1.19 and a fifty-two week high of $2.82.
Hedge funds have recently bought and sold shares of the business. Citigroup Inc. raised its position in Eyepoint Pharmaceuticals by 293.6% in the 4th quarter. Citigroup Inc. now owns 21,027 shares of the company’s stock valued at $33,000 after purchasing an additional 15,685 shares in the last quarter. Creative Planning acquired a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $47,000. Barclays PLC raised its position in Eyepoint Pharmaceuticals by 93.5% in the 4th quarter. Barclays PLC now owns 63,060 shares of the company’s stock valued at $98,000 after purchasing an additional 30,473 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Eyepoint Pharmaceuticals by 32.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 80,703 shares of the company’s stock valued at $125,000 after purchasing an additional 20,001 shares in the last quarter. Finally, UBS Group AG raised its position in Eyepoint Pharmaceuticals by 138.4% in the 4th quarter. UBS Group AG now owns 87,219 shares of the company’s stock valued at $135,000 after purchasing an additional 50,637 shares in the last quarter. 56.89% of the stock is currently owned by institutional investors.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Read More: Treasury Bonds
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.